Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02047318
Other study ID # LUM001-303
Secondary ID 2013-003832-54
Status Completed
Phase Phase 2
First received
Last updated
Start date December 20, 2013
Est. completion date June 17, 2020

Study information

Verified date November 2021
Source Mirum Pharmaceuticals, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this extension study is to determine the long-term safety and tolerability of an investigational treatment (LUM001 also known as Maralixibat) in children with ALGS who have completed participation in a core LUM001 treatment protocol. Efficacy will be assessed by evaluating the effect of LUM001 on pruritus, biochemical markers of pruritus, as well as biochemical markers of cholestasis and liver disease.


Recruitment information / eligibility

Status Completed
Enrollment 19
Est. completion date June 17, 2020
Est. primary completion date June 17, 2020
Accepts healthy volunteers No
Gender All
Age group 12 Months to 18 Years
Eligibility Participation for an individual patient is expected to be approximately 72 weeks. Patients who complete 72 weeks of treatment may be eligible to receive treatment for up to 52 weeks during the follow-up treatment period and patients who completed the 124 weeks of treatment may be eligible to enter the additional long-term follow-up period.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
LUM001 (Maralixibat)
Dosing of LUM001 also known as Maralixibat (MRX) with the objective of achieving optimal control of pruritus at a dose level that is tolerated by the participant and up to a maximum daily dose of 560 micrograms per kilogram (mcg/kg).

Locations

Country Name City State
United Kingdom Birmingham Children's Hospital Birmingham West Midlands
United Kingdom Leeds Teaching Hospital NHS Trust Leeds West Yorkshire
United Kingdom Kings College Hospital London

Sponsors (1)

Lead Sponsor Collaborator
Mirum Pharmaceuticals, Inc.

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change From MRX Baseline to Week 48 in Fasting sBA Levels The primary endpoint of this study was the mean change from MRX baseline to Week 48 in fasting sBA level. MRX baseline to Week 48
Secondary Change From MRX Baseline Over Time in Fasting sBA Levels This secondary efficacy endpoint is the mean change from MRX baseline over time in fasting sBA levels. Results reported here are the long-term results. MRX baseline to End of Treatment (maximum exposure was 336 weeks)
Secondary Change From MRX Baseline to Week 48 in Pruritus This secondary efficacy endpoint is the change from MRX baseline to Week 48 in pruritus as measured by ItchRO(Obs) weekly average morning severity score. ItchRO scores range from 0 to 4; the higher score indicates increasing itch severity (0 = none; 4 = very severe). MRX baseline to Week 48
Secondary Change From MRX Baseline Over Time in Pruritus This secondary efficacy endpoint is the change from MRX baseline over time in pruritus as measured by ItchRO(Obs) weekly average morning severity score. ItchRO scores range from 0 to 4; the higher score indicates increasing itch severity (0 = none; 4 = very severe). Results reported here are the long-term results. MRX baseline to End of Treatment (maximum exposure was 336 weeks)
Secondary Change From MRX Baseline to Week 48 in Clinician Xanthoma Severity Score This secondary efficacy endpoint is the mean change from MRX baseline to Week 48 in clinician xanthoma severity scores. It is based on a 0-4 scale to rate the number of lesions present and the degree to which the participant's lesions interfere or limit his or her activities. Clinician xanthoma severity scores range from 0 to 4, with a xanthoma score of zero representing no evidence of xanthomatosis and a score of 4 representing xanthoma so severe that it is disabling. Clinician xanthoma severity scores were not assessed in Study LUM001-302 so mean clinician xanthoma severity score at MRX baseline was calculated from the 5 participants who were assigned to placebo in Study LUM001-302, and analysis of change from MRX baseline is not presented. MRX baseline to Week 48
Secondary Change From MRX Baseline Over Time in Clinician Xanthoma Severity Score This secondary efficacy endpoint is the mean change from MRX baseline over time (with Week 252 chosen as the end point, as the last analysis visit with at least 6 participants) in clinician xanthoma severity scores. It is based on a 0-4 scale to rate the number of lesions present and the degree to which the lesions interfere or limit activities. Clinician xanthoma severity scores range from 0 to 4, with a score of zero representing no evidence of xanthomatosis and a score of 4 representing xanthoma so severe that it is disabling. Clinician xanthoma severity scores were not assessed in Study LUM001-302 so mean clinician xanthoma severity score at MRX baseline was calculated from the 5 participants assigned to placebo in Study LUM001-302, and analysis of change from MRX baseline is not presented. Results reported here are the long-term results. MRX baseline to End of Treatment (maximum exposure was 336 weeks)
Secondary Secondary: Change From MRX Baseline to Week 48 in Alkaline Phosphatase This secondary efficacy endpoint is the mean change from MRX baseline to Week 48 in ALP. MRX baseline to Week 48
Secondary Change From MRX Baseline Over Time in Alkaline Phosphatase This secondary efficacy endpoint is the mean change from MRX baseline over time in ALP. Results reported here are the long-term results. MRX baseline to end of treatment (maximum exposure was 336 weeks)
Secondary Change From MRX Baseline to Week 48 in Alanine Aminotransferase This secondary efficacy endpoint is the mean change from MRX baseline to Week 48 in ALT. MRX baseline to Week 48
Secondary Change From MRX Baseline Over Time in Alanine Aminotransferase This secondary efficacy endpoint is the mean change from MRX baseline over time in ALT levels. Results reported here are the long-term results. MRX baseline to End of Treatment (maximum exposure was 336 weeks)
Secondary Change From MRX Baseline to Week 48 in Aspartate Aminotransferase This secondary efficacy endpoint is the mean change from MRX baseline to Week 48 in AST levels. MRX baseline to Week 48
Secondary Change From MRX Baseline Over Time in Aspartate Aminotransferase This secondary efficacy endpoint is the mean change from MRX baseline over time in AST levels. Results reported here are the long-term results. MRX baseline to End of treatment (maximum exposure was 336 weeks)
Secondary Change From MRX Baseline to Week 48 in Gamma Glutamyltransferase This secondary efficacy endpoint is the mean change from MRX baseline to Week 48 in GGT. MRX baseline to Week 48
Secondary Change From MRX Baseline Over Time in Gamma Glutamyltransferase This secondary efficacy endpoint is the mean change from MRX baseline over time in GGT. Results reported here are the long-term results. MRX baseline to End of Treatment (maximum exposure was 336 weeks)
Secondary Change From MRX Baseline to Week 48 in Total and Direct Bilirubin This secondary efficacy endpoint is the mean change from MRX baseline to Week 48 in total bilirubin and direct bilirubin. MRX baseline to Week 48
Secondary Change From MRX Baseline Over Time in Total and Direct Bilirubin This secondary efficacy endpoint is the mean change from MRX baseline over time in total bilirubin and direct bilirubin. Results reported here are the long-term results. MRX baseline to End of Treatment (maximum exposure was 336 weeks)
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04729751 - A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS). Phase 2
Active, not recruiting NCT05035030 - Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome Phase 3
Recruiting NCT06193928 - Long-Term Safety and Clinical Outcomes of Livmarli in Patients With Alagille Syndrome (LEAP)
Completed NCT02160782 - Safety and Efficacy Study of LUM001 (Maralixibat) With a Drug Withdrawal Period in Participants With Alagille Syndrome (ALGS) Phase 2
Completed NCT00007033 - Study of Magnesium Sulfate in Children With Reduced Bone Density Secondary to Chronic Cholestatic Liver Disease N/A
Suspended NCT00571272 - Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis (LOGIC)
Completed NCT02057692 - Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome Phase 2
Active, not recruiting NCT02922751 - FibroScan™ in Pediatric Cholestatic Liver Disease (FORCE)
Completed NCT00001642 - Positional Cloning of the Gene(s) Responsible for Alagille Syndrome N/A
Recruiting NCT05488067 - Atorvastatin Therapy on Xanthoma in Alagille Syndrome Phase 4
Completed NCT04674761 - Efficacy and Safety of Odevixibat in Patients With Alagille Syndrome Phase 3
Completed NCT02117713 - An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome Phase 2
Completed NCT02131623 - Validation of the Itch Reported Outcome (ItchRO) Diaries in Pediatric Cholestatic Liver Disease
Completed NCT02963077 - A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384 Phase 1
Recruiting NCT01793168 - Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Completed NCT03082937 - An Open Label, Single-dose, Single Period ADME Study of A4250 in Healthy Subjects Phase 1
Completed NCT01903460 - Safety and Efficacy Study of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Alagille Syndrome Phase 2
Completed NCT01515631 - Characterization of Pulmonary Artery Stenoses in Alagille Syndrome - a Medical Record Review
Enrolling by invitation NCT05846854 - Decreasing Hemorrhage Risk in Children With Alagille Syndrome N/A
Approved for marketing NCT04530994 - A Maralixibat Expanded Access Program for Patients With Cholestatic Pruritus Associated With Alagille Syndrome (ALGS)